Kite Pharma, a wholly-owned subsidiary of Gilead Sciences, announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics for a total of $350 million in cash consideration. Interius BioTherapeutics is a clinical-stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an […]
The post Kite Acquires Interius BioTherapeutics to Advance In Vivo Platform appeared first on LevinPro Healthcare M&A – The latest healthcare M&A news.
